← All drugs
Drug · FAERS side-effect profile with label screen

Escitalopram side effects: what 139,448 FDA adverse event reports show

Escitalopram · Escitalopram Oxalate · 1,163 reaction terms · 570,776 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Selective serotonin reuptake inhibitor (ssri)

FDA label, Indications wording

Brand names

Escitalopram Oxalate

openFDA label

Who reports

139,448 reports · 67% serious · 11,263 with death outcome · 69% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Escitalopram oral solution is indicated for the treatment of: major depressive disorder (MDD) in adults and pediatric patients 12 years of age and older. generalized anxiety disorder (GAD) in adults. Additional pediatric use information is approved for AbbVie Inc.’s LEXAPRO (escitalopram) oral solution.

FDA label, Indications and Usage

What it is

Escitalopram is a 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile that has S-configuration at the chiral centre.

PubChem CID 146570 (ChEBI)

Boxed warning

SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies . Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1) ] .

FDA label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled — boxed warning 2Labeled adverse reaction 4Labeled (related wording) 6Lab value / disease marker 4Not in label — unassessed 24
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,123 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Spirometry abnormal288145.3
123.5–171.0ROR 145.6 · calibrated p 7e-9 ✓
73.3 EB05 66.5 · IC025 +5.8
3/3 methods agree
Lab value / disease markerserious n=288 · ♀ 0% (drug 69%)no trial arm names this drug
Total lung capacity abnormal13380.6
65.3–99.6ROR 80.7 · calibrated p 7e-7 ✓
52.1 EB05 45.1 · IC025 +5.2
3/3 methods agree
Not in label — unassessedserious n=132 · ♀ 0% (drug 69%) · 100% clinicianno trial arm names this drug
Mycotic allergy27472.3
62.6–83.6ROR 72.5 · calibrated p 1e-6 ✓
48.7 EB05 44.0 · IC025 +5.3
3/3 methods agree
Not in label — unassessedserious n=271 · ♀ 0% (drug 69%)no trial arm names this drug
Pulmonary vasculitis15562.2
51.6–75.1ROR 62.3 · calibrated p 4e-6 ✓
43.8 EB05 38.3 · IC025 +5.0
3/3 methods agree
Not in label — unassessedserious n=155 · ♀ 0% (drug 69%) · 100% clinicianno trial arm names this drug
Dust allergy27559.8
52.0–68.8ROR 60.0 · calibrated p 5e-6 ✓
42.7 EB05 38.7 · IC025 +5.1
3/3 methods agree
Not in label — unassessedserious n=272 · ♀ 0% (drug 69%)no trial arm names this drug
Amaurosis fugax24344.0
38.2–50.8ROR 44.1 · calibrated p 3e-5 ✓
34.1 EB05 30.6 · IC025 +4.8
3/3 methods agree
Not in label — unassessedserious n=243 · 100% clinicianno trial arm names this drug
Vital capacity decreased10143.3
34.7–54.0ROR 43.3 · calibrated p 4e-5 ✓
33.5 EB05 28.3 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious n=101 · ♀ 100% (drug 69%) · 100% clinicianno trial arm names this drug
Conjunctivitis allergic29537.8
33.3–43.0ROR 37.9 · calibrated p 8e-5 ✓
30.3 EB05 27.5 · IC025 +4.7
3/3 methods agree
Not in label — unassessedserious n=293 · ♀ 0% (drug 69%)no trial arm names this drug
Reversible airways obstruction10237.0
29.8–46.0ROR 37.0 · calibrated p 1e-4 ✓
29.6 EB05 25.1 · IC025 +4.4
3/3 methods agree
Not in label — unassessedserious n=102 · ♀ 100% (drug 69%) · 100% clinicianno trial arm names this drug
Steroid dependence16736.6
30.9–43.4ROR 36.7 · calibrated p 1e-4 ✓
29.4 EB05 25.9 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious n=167 · ♀ 0% (drug 69%) · 100% clinicianno trial arm names this drug
Catarrh15331.1
26.1–37.0ROR 31.1 · calibrated p 2e-4 ✓
25.8 EB05 22.5 · IC025 +4.3
3/3 methods agree
Not in label — unassessedserious n=153 · ♀ 0% (drug 69%) · 100% clinicianno trial arm names this drug
Antineutrophil cytoplasmic antibody positive10525.2
20.5–31.0ROR 25.2 · calibrated p 7e-4 ✓
21.6 EB05 18.3 · IC025 +4.0
3/3 methods agree
Lab value / disease markerserious n=105 · ♀ 0% (drug 69%) · 100% clinicianno trial arm names this drug
Sputum culture positive10622.1
18.0–27.1ROR 22.1 · calibrated p 0.001 ✓
19.3 EB05 16.4 · IC025 +3.8
3/3 methods agree
Lab value / disease markerserious n=105 · ♀ 100% (drug 69%) · 100% clinicianno trial arm names this drug
Physical deconditioning30320.6
18.3–23.2ROR 20.6 · calibrated p 0.002 ✓
18.2 EB05 16.5 · IC025 +4.0
3/3 methods agree
Not in label — unassessedserious n=301no trial arm names this drug
Neuritis16317.7
15.1–20.8ROR 17.7 · calibrated p 0.004 ✓
15.9 EB05 13.9 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious n=161 · ♀ 0% (drug 69%) · 100% clinicianno trial arm names this drug
Normochromic normocytic anaemia30216.7
14.8–18.8ROR 16.8 · calibrated p 0.004 ✓
15.1 EB05 13.7 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious n=302 · ♀ 0% (drug 69%)no trial arm names this drug
Burns second degree17116.2
13.8–19.0ROR 16.2 · calibrated p 0.005 ✓
14.6 EB05 12.9 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious n=170 · ♀ 0% (drug 69%) · 100% clinicianno trial arm names this drug
Serotonin syndrome1,66814.3
13.6–15.0ROR 14.4 · calibrated p 0.008 ✓
13.1 EB05 12.6 · IC025 +3.6
3/3 methods agree
Labeled — boxed warning
exact term
age-adj. PRR 9.5 · serious PRR 11.2no trial arm names this drug
Reversible cerebral vasoconstriction syndrome16814.0
11.9–16.4ROR 14.0 · calibrated p 0.010 ✓
12.8 EB05 11.2 · IC025 +3.4
3/3 methods agree
Not in label — unassessedserious n=168 · ♀ 100% (drug 69%) · 100% clinicianno trial arm names this drug
Eosinophilic granulomatosis with polyangiitis16012.9
10.9–15.1ROR 12.9 · calibrated p 0.013 ✓
11.8 EB05 10.3 · IC025 +3.3
3/3 methods agree
Not in label — unassessedserious n=160 · ♀ 0% (drug 69%) · 100% clinicianno trial arm names this drug
Sleep talking11310.6
8.7–12.8ROR 10.6 · calibrated p 0.028 ✓
9.8 EB05 8.3 · IC025 +2.9
3/3 methods agree
Not in label — unassessedserious n=91 · ♀ 0% (drug 69%) · 100% consumerno trial arm names this drug
Alcohol poisoning1609.6
8.2–11.2ROR 9.6 · calibrated p 0.038 ✓
8.9 EB05 7.8 · IC025 +2.9
3/3 methods agree
Not in label — unassessedserious n=156 · ♀ 0% (drug 69%) · 100% clinicianno trial arm names this drug
Anorgasmia1589.2
7.8–10.8ROR 9.2 · calibrated p 0.044 ✓
8.6 EB05 7.5 · IC025 +2.8
3/3 methods agree
Labeled adverse reaction
exact term
serious n=120 · ♀ 44% (drug 69%) · 100% consumerno trial arm names this drug
Gun shot wound1099.1
7.5–11.0ROR 9.1 · calibrated p 0.046 ✓
8.4 EB05 7.2 · IC025 +2.7
3/3 methods agree
Not in label — unassessedserious n=107 · ♀ 0% (drug 69%) · 100% consumerno trial arm names this drug
Hypopnoea1938.8
7.6–10.2ROR 8.8 · calibrated p 0.050 ✓
8.3 EB05 7.3 · IC025 +2.8
3/3 methods agree
Not in label — unassessedserious n=184 · ♀ 0% (drug 69%) · 100% clinicianno trial arm names this drug
Electric shock sensation1458.5
7.2–10.1ROR 8.5 · calibrated p 0.056
8.0 EB05 6.9 · IC025 +2.7
3/3 methods agree
Labeled adverse reaction
exact term
serious n=126 · 100% consumerno trial arm names this drug
Clonus1458.3
7.1–9.9ROR 8.3 · calibrated p 0.060
7.8 EB05 6.8 · IC025 +2.7
3/3 methods agree
Labeled adverse reaction
exact term
serious n=144 · 100% clinicianno trial arm names this drug
Forced expiratory volume decreased1458.0
6.8–9.5ROR 8.1 · calibrated p 0.067
7.5 EB05 6.6 · IC025 +2.6
3/3 methods agree
Lab value / disease markerserious n=144 · ♀ 0% (drug 69%) · 100% clinicianno trial arm names this drug
Sleep terror2087.8
6.8–8.9ROR 7.8 · calibrated p 0.074
7.3 EB05 6.5 · IC025 +2.6
3/3 methods agree
Not in label — unassessedserious n=186 · ♀ 0% (drug 69%)no trial arm names this drug
Hyperreflexia1717.7
6.6–8.9ROR 7.7 · calibrated p 0.077
7.2 EB05 6.4 · IC025 +2.6
3/3 methods agree
Labeled adverse reaction
exact term
serious n=166 · 100% clinicianno trial arm names this drug
Hyperparathyroidism secondary1237.6
6.4–9.1ROR 7.6 · calibrated p 0.079
7.1 EB05 6.1 · IC025 +2.5
3/3 methods agree
Not in label — unassessedserious n=123no trial arm names this drug
Sexual dysfunction5587.5
6.9–8.2ROR 7.5 · calibrated p 0.080
7.1 EB05 6.7 · IC025 +2.7
3/3 methods agree
Labeled — boxed warning
exact term
serious PRR 7.4 · ♀ 35% (drug 69%) · 71% consumerno trial arm names this drug
Nephrogenic anaemia2197.3
6.4–8.4ROR 7.4 · calibrated p 0.087
7.0 EB05 6.2 · IC025 +2.6
3/3 methods agree
Not in label — unassessedserious n=219no trial arm names this drug
Haemorrhagic stroke3557.1
6.4–7.9ROR 7.1 · calibrated p 0.096
6.7 EB05 6.2 · IC025 +2.6
3/3 methods agree
Not in label — unassessedserious PRR 5.8 · ♀ 0% (drug 69%)no trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Suicidality8,1075.15.0–5.2signal
Depression7,5684.14.0–4.2signal
Extrapyramidal2,3613.43.3–3.6signal
Hyponatraemia1,7683.43.2–3.5signal
Fall / fracture5,8412.32.3–2.4signal
Arrhythmia / qt2,8702.22.2–2.3signal
Seizure2,6302.02.0–2.1raised
Venous thromboembolism2,8832.01.9–2.1raised
Rhabdomyolysis / myopathy9331.71.6–1.9raised
Pancreatitis9251.71.6–1.8raised
Gi bleeding1,9901.61.6–1.7raised
Serious infection7,2391.41.4–1.4raised
Kidney injury4,1921.41.3–1.4raised
Anaemia2,7221.41.3–1.4raised
Stroke2,2461.41.3–1.4raised
Hyperglycaemia / diabetes3,0921.31.3–1.4raised

Trial evidence (ClinicalTrials.gov)

ClinicalTrials.gov returned results-bearing trials mentioning Escitalopram only as a background or rescue medication (NCT01360866, NCT01838681); no trial listing it as the tested intervention was cached, so no trial cross-check is shown.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Fatigue (tiredness)9,5431.9
1.8–1.9ROR 1.9 · calibrated p 0.900
1.8 EB05 1.8 · IC025 +0.9Labeled adverse reaction
exact term
age-adj. PRR 1.6 · serious PRR 1.8no trial arm names this drug
Nausea9,5181.8
1.8–1.9ROR 1.9 · calibrated p 0.879
1.8 EB05 1.8 · IC025 +0.8Labeled adverse reaction
exact term
age-adj. PRR 1.5 · serious PRR 1.9no trial arm names this drug
Drug ineffective (drug did not work)8,9961.0
1.0–1.0ROR 1.0 · calibrated p 0.325
1.0 EB05 1.0 · IC025 +0.0Reporting / coding artifactage-adj. PRR 1.1 · serious PRR 1.4no trial arm names this drug
Headache7,3971.8
1.7–1.8ROR 1.8 · calibrated p 0.847
1.8 EB05 1.7 · IC025 +0.8Labeled adverse reaction
exact term
age-adj. PRR 1.5 · serious PRR 2.0no trial arm names this drug
Diarrhoea (diarrhea)7,0451.7
1.6–1.7ROR 1.7 · calibrated p 0.762
1.6 EB05 1.6 · IC025 +0.7Labeled adverse reaction
exact term
age-adj. PRR 1.4 · serious PRR 1.6no trial arm names this drug
Anxiety6,6683.6
3.5–3.7ROR 3.7 · calibrated p 0.437
3.5 EB05 3.4 · IC025 +1.8
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
age-adj. PRR 3.4 · serious PRR 3.4no trial arm names this drug
Dizziness6,3111.9
1.9–2.0ROR 2.0 · calibrated p 0.922
1.9 EB05 1.9 · IC025 +0.9Labeled adverse reaction
exact term
age-adj. PRR 1.7 · serious PRR 2.0no trial arm names this drug
Off label use (used outside approved label)6,2081.1
1.0–1.1ROR 1.1 · calibrated p 0.359
1.1 EB05 1.1 · IC025 +0.1Reporting / coding artifactage-adj. PRR 1.0 · serious PRR 1.2no trial arm names this drug
Depression6,1554.1
4.0–4.2ROR 4.3 · calibrated p 0.329
4.0 EB05 4.0 · IC025 +2.0
3/3 methods agree
Labeled — boxed warning
synonym match
age-adj. PRR 3.7 · serious PRR 3.8no trial arm names this drug
Pain5,8211.4
1.4–1.5ROR 1.4 · calibrated p 0.605
1.4 EB05 1.4 · IC025 +0.5Labeled adverse reaction
exact term
age-adj. PRR 1.5 · serious PRR 1.4no trial arm names this drug
Fall5,5772.5
2.5–2.6ROR 2.6 · calibrated p 0.766
2.5 EB05 2.5 · IC025 +1.3
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.3 · serious PRR 2.2no trial arm names this drug
Dyspnoea (shortness of breath)5,4931.5
1.4–1.5ROR 1.5 · calibrated p 0.631
1.5 EB05 1.4 · IC025 +0.5Labeled adverse reaction
exact term
age-adj. PRR 1.3 · serious PRR 1.4no trial arm names this drug
Vomiting5,3011.7
1.7–1.8ROR 1.7 · calibrated p 0.791
1.7 EB05 1.7 · IC025 +0.7Labeled adverse reaction
exact term
age-adj. PRR 1.5 · serious PRR 1.7no trial arm names this drug
Insomnia (trouble sleeping)4,4912.6
2.5–2.6ROR 2.6 · calibrated p 0.768
2.5 EB05 2.5 · IC025 +1.3
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.1 · serious PRR 2.7no trial arm names this drug
Asthenia (weakness)4,4571.8
1.7–1.8ROR 1.8 · calibrated p 0.840
1.8 EB05 1.7 · IC025 +0.8Labeled adverse reaction
exact term
age-adj. PRR 1.5 · serious PRR 1.7no trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Escitalopram ↔ QT prolongation.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Escitalopram?

In FDA FAERS, the most frequently co-reported reaction terms for Escitalopram are fatigue, nausea, headache, diarrhoea, anxiety, dizziness. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Escitalopram have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies . Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1) ] .

Do FAERS signals prove that Escitalopram causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.